Posted on 3/8/12 via Reuters.
Merck's hepatitis C drug wins UK cost endorsement
LONDON, March 9 | Fri Mar 9, 2012 12:01am GMT
(Reuters) - U.S. drugmaker Merck & Co's new hepatitis C drug Victrelis was recommended for use within Britain's state health service on Friday, despite its hefty price tag.
The National Institute for Health and Clinical Excellence, which often spurns expensive new medicines on cost grounds, said significant improvements seen with Victrelis made it a cost-effective option.
The drug, also known as boceprevir, is designed for use in combination with peginterferon alfa and ribavirin for patients with liver disease due to genotype 1 chronic hepatitis C, the most common form.
Posts
No comments:
Post a Comment